Erste Group Bank Analysts Lift Earnings Estimates for Amgen

Amgen Inc. (NASDAQ:AMGN) – Erste Group Bank upped their FY2026 earnings estimates for Amgen in a note issued to investors on Wednesday, February 18th. Erste Group Bank analyst H. Engel now forecasts that the medical research company will earn $22.36 per share for the year, up from their prior estimate of $22.28. Erste Group Bank currently has a “Buy” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

A number of other equities analysts also recently issued reports on AMGN. Cantor Fitzgerald increased their price objective on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research note on Monday, December 29th. Daiwa Securities Group lifted their target price on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Oppenheimer set a $400.00 target price on shares of Amgen and gave the company an “outperform” rating in a research report on Thursday, January 29th. Finally, Citigroup raised their price target on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $351.76.

Amgen Stock Performance

Shares of Amgen stock opened at $382.87 on Monday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock’s fifty day moving average price is $345.41 and its 200-day moving average price is $317.87. The firm has a market cap of $206.39 billion, a P/E ratio of 26.91, a P/E/G ratio of 3.76 and a beta of 0.46. Amgen has a 12 month low of $261.43 and a 12 month high of $385.12.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter last year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.6%. This is a boost from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio is currently 70.84%.

Institutional Trading of Amgen

A number of large investors have recently made changes to their positions in the company. DGS Capital Management LLC increased its position in Amgen by 17.1% in the 4th quarter. DGS Capital Management LLC now owns 2,089 shares of the medical research company’s stock valued at $684,000 after acquiring an additional 305 shares during the period. Astoria Portfolio Advisors LLC. grew its stake in shares of Amgen by 31.1% during the 4th quarter. Astoria Portfolio Advisors LLC. now owns 1,871 shares of the medical research company’s stock worth $612,000 after purchasing an additional 444 shares during the period. SG Trading Solutions LLC purchased a new position in shares of Amgen in the 4th quarter valued at about $1,041,000. Investment Insight Wealth Management LLC acquired a new stake in shares of Amgen in the fourth quarter valued at about $205,000. Finally, Monetary Solutions Ltd purchased a new stake in Amgen during the fourth quarter worth about $118,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Market commentary highlighting recent share-strength and valuation checks has drawn fresh investor attention, supporting momentum off strong YTD and 1‑year returns. Amgen (AMGN) Valuation Check After Recent Share Price Strength And Analyst Fair Value Debate
• Positive Sentiment: Multiple articles argue Amgen is a long-term value/dividend play, reinforcing buy-and-hold interest from income and value-focused investors. Why Amgen (AMGN) is a Top Value Stock for the Long-Term (Zacks)
• Positive Sentiment: Amgen scheduled a presentation at the TD Cowen Health Care Conference (March 2), giving management a platform to update on commercial outlook and the MARITIME trial timetable — a likely near‑term liquidity for investor sentiment. AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
• Neutral Sentiment: Short interest data posted shows zero shares and a short-interest ratio of 0.0 days — this appears to be a reporting anomaly and doesn’t provide a clear signal on bearish positioning.
• Neutral Sentiment: Feature pieces and retrospectives on long‑term returns (Benzinga, MSN) boost narrative momentum but are not new fundamental catalysts. If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today
• Negative Sentiment: Barclays initiated coverage with an Equal Weight rating and a $185 price target — a relatively conservative view that could cap upside and prompt some profit‑taking or more cautious positioning among institutional holders. Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.